MiMedx Group, Inc. reaffirmed revenue guidance for 2022. The Company is maintaining its outlook for 2022, as disclosed in its earnings release for the year ended December 31, 2021, including that it expects net sales of its continuing portfolio of Advanced Wound Care products, which were $240.0 million in 2021, to grow 11% to 14% in 2022. These expectations reflect the Company's plans to launch AMNIOEFFECT and its Placental Collagen Matrix product, AXIOFILL, in the U.S. in September, as well as the launch of EPIFIX® in Japan later this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.24 USD | +0.56% | -3.47% | -17.45% |
Apr. 30 | Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024 | |
Apr. 30 | Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.45% | 1.06B | |
-21.29% | 129M | |
+5.63% | 71.46M | |
+5.15% | 60.45M | |
+11.78% | 58.25M | |
-1.20% | 51.85M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- MiMedx Group, Inc. Reaffirms Revenue Guidance for 2022